
Interleukin-6 (IL-6) orchestrates inflammatory, metabolic, and tissue-repair programs, and when dysregulated contributes to autoimmune, hyperinflammatory, and malignant diseases. Although transcriptional induction and IL-6 Receptor (IL-6R)-gp130 signaling complex are well defined, post-transcriptional and epi-transcriptional programs that determine Il6 mRNA fate govern the amplitude and persistence of IL-6 responses. The AT-rich interaction domain-containing protein 5a (Arid5a)-Regnase-1 emerges as a dominant rheostat. Arid5a binds structured elements in the 3′ Untranslated region (3′UTR) to stabilize Il6 and amplify pathogenic output, particularly cytokine storm and T helper 17 (Th17)-linked inflammatory phenotypes. Regnase-1 recognizes 3′UTR structures and, through Up-frameshift protein 1 (UPF1)-SMG1 licensing during the pioneer round of translation, promotes resolution by destabilizing Il6 mRNA and limiting cytokine supply. Epi-transcriptional tuning provides secondary control. N6-Methyladenosine (m6A) writer-eraser-reader programs regulate export, stability, and translation of inflammatory transcripts, while Adenosine deaminases acting on RNA 2 (ADAR2) editing in endothelium preserves gp130 and sustains trans-signaling. This review synthesizes Il6 mRNA regulation, IL-6R signaling, and clinical IL-6/IL-6R blockade including Tocilizumab (TCZ) within an RNA layer framework that calibrates IL-6 output and delineates biomarker- and signaling-guided horizons where RNA layer modulation may complement IL-6 directed therapies to advance precision immunomodulation.
Whether p53-driven immune modulation represents a conserved biological programme or a context-dependent adaptation of the tumour microenvironment remains unresolved across human cancers. To address this question, we investigated the relationship between TP53 expression, p53 pathway activity and immune microenvironmental features in breast, colorectal and kidney cancers through integrated transcriptomic, histological and bioinformatic analyses. Our findings revealed striking tumour-specific patterns of p53-associated immune regulation. Breast cancer showed no significant relationship between TP53 expression, p53 pathway activity and immune infiltration or immune checkpoint expression, consistent with an intrinsically immune-cold microenvironment. In contrast, colorectal cancer exhibited a paradoxical immune-restricted phenotype in which p53 pathway activation coexisted with increased cytotoxic lymphocyte infiltration while simultaneously associating with the upregulation of the inhibitory checkpoints TIM-3 and VISTA. Analyses of public colorectal cancer datasets showed frequent TP53 mutations and higher TP53 transcript expression in primary tumours and metastatic lesions than in normal colon tissue. Kidney cancer displayed a distinct stromal-centred pattern, where TP53 expression, but not p53 pathway activity, was associated with fibroblast enrichment and increased expression of immunoregulatory checkpoints. In conclusion, this study reveals distinct associations between p53 signalling and immune microenvironmental features, supporting a context-dependent role of p53 in tumour immune regulation. These data may inform future studies exploring the integration of p53-related biomarkers with immunotherapeutic strategies. TP53 shapes tumour-specific immune phenotypes across epithelial cancers. Breast cancer shows no association between TP53 activity and immune infiltration. Colorectal cancer exhibits a TP53-linked TIM-3/VISTA immune-restricted phenotype. TP53-TIM-3-VISTA co-expression identifies colorectal cancer patients with worse survival. Kidney cancer shows a TP53-associated stromal and immunoregulatory checkpoint profile.
Autosomal dominant polycystic kidney disease (ADPKD) initiates long before cysts appear, yet the molecular triggers of this precystic phase remain poorly defined. To gain more insight into these early alterations, we applied cross-species Weighted Gene Coexpression Network Analysis (WGCNA) to renal transcriptomes from inducible Pkd1-knockout (iKsp-Pkd1del) mice across precystic and cystic stages. Instead of constructing a new network, expression profiles were projected onto three hundred and forty-seven curated rat kidney co-expression modules from the TXG-MAPr framework, enabling direct systems-level comparison with conserved injury signatures. Forty-two transcriptionally active modules emerged, including twenty-one already deregulated during the morphologically normal precystic phase. Early upregulated modules showed activation of circadian regulators (Bmal1/Arntl, Per1, Per3, Npas2) and sterol biosynthesis under Srebf2 control, whereas mitochondrial and oxidative-phosphorylation modules were markedly repressed. Transcription-factor enrichment revealed distinct regulatory axes: circadian control by BMAL1, metabolic regulation through SREBP2 (encoded by Srebf2), and inflammatory/cytokine signaling mediated by STAT3, p53, and NF-κB. These regulatory programs diverged transcriptionally within two weeks of Pkd1 loss, establishing an epithelial-driven phase characterized by circadian misalignment, metabolic rewiring, mitochondrial suppression and concomitant low-level inflammatory signaling. Inflammatory and stress-response modules intensified during later cystic stages. Notably, Pkd2 clustered within a small but transcriptionally active high-ranked module suggesting early perturbation of the polycystin complex. Together, these data define precystic ADPKD as a convergence of independent epithelial programs accompanied by early inflammatory engagement that precedes overt cyst expansion, providing a modular framework for early biomarker discovery and therapeutic targeting.
Undifferentiated/dedifferentiated endometrial carcinoma (UDEC) represents a rare but aggressive subtype of endometrial cancer characterized by chemoresistance. Notably, a considerable proportion of patients with UDEC who exhibit mismatch repair deficiency respond favorably to immunotherapy. Here, we identified mutations in the ribosomal protein L22 (RPL22) gene in 42
Age-related hearing loss (ARHL) is a prevalent and debilitating sensory deficit in the elderly, with chronic inflammation being a key pathogenic driver. The RNA methyltransferase METTL3, a primary mediator of N6-methyladenosine (m6A) modification, has been implicated in various aging-related diseases; however, its functional role and mechanism in ARHL remain poorly defined. ARHL models were established using 12-month-old C57BL/6 mice and by treating HEI-OC1 auditory cells with LPS and D-galactose. Auditory function and cochlear pathology were assessed through auditory brainstem response (ABR) thresholds and hematoxylin-eosin (H&E) staining, respectively. Inflammatory cytokine levels, gene and protein expression, were measured using ELISA, qPCR, Western blotting, and immunofluorescence. The molecular mechanism of METTL3 in inflammation was investigated using m6A RNA methylation quantification kit, RIP-qPCR analysis, and RNA stability assay. We found that both NFKBIA and METTL3 were significantly downregulated in the cochleae of ARHL mice. In HEI-OC1 cells, overexpression of NFKBIA suppressed the NLRP3 inflammasome and the pro-inflammatory NF-kappa B/IL-6/STAT3 axis. Furthermore, METTL3 overexpression mitigated NF-kappa B-mediated inflammation, an effect that was significantly attenuated upon NFKBIA knockdown. Mechanistically, METTL3 directly bound to NFKBIA mRNA and enhanced its stability through m6A modification. Critically, in ARHL mice, METTL3 overexpression restored NFKBIA levels, ameliorated hearing loss and cochlear damage, and suppressed the activation of the NLRP3 inflammasome and the NF-kappa B/IL-6/STAT3 pathway. Collectively, METTL3 mitigated ARHL by downregulating the NF-kappa B/IL-6/STAT3/NLRP3-mediated inflammatory responses through the enhancement of NFKBIA m6A modification.